According to TCGA pan cancer studies, ATM mutations are found in approximately 5.3% of all cancers and are most common in uterine corpus endometrial cancer (19.1%) followed by bladder urothelial cancer (13.4%) and colorectal adenocarcinoma (13.1%). This evidence concerns the gene ATM and cancer.